R-H. Xu

机构：North China Electric Power University, Sun Yat-sen University, ShenZhen People’s Hospital, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China

发表论文 65 篇 · 总被引 202 次 · h-index 8

代表论文

2094O SKYSCRAPER-07: A phase III, randomised study of atezolizumab (atezo) with or without tiragolumab (tira) in patients (pts) with unresectable esophageal squamous cell carcinoma (ESCC) that has not progressed following definitive concurrent chemoradiotherapy (dCRT) (2025 · Annals of Oncology · 被引 8)
In Situ Formation of Mechanically Interlocked Heterointerfaces with Ultrahigh Bonding Strength for Mg‐Based Multilayered Sheets (2025 · Advanced Science · 被引 5)
2136P ASP2138 monotherapy or in combination with pembrolizumab and mFOLFOX6 or with ramucirumab and paclitaxel in claudin 18 isoform 2 (CLDN18.2) + locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Phase I/Ib trial (2025 · Annals of Oncology · 被引 4)
263TiP TroFuse-015: A phase III study of trophoblast antigen 2 (TROP2)–directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA) (2024 · Annals of Oncology · 被引 3)
392MO Recurrent patient-reported outcome (PRO)-based deterioration predicts overall survival (OS) in patients with advanced gastric adenocarcinoma with PD-L1 score of ≥5%: Results from the RATIONALE-305 trial (2025 · Annals of Oncology · 被引 2)
669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (2025 · Annals of Oncology · 被引 1)